Naltrexone Tablet and Placebo Patch — Competitive Intelligence Brief

Naltrexone Tablet and Placebo Patch (Naltrexone Tablet and Placebo Patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Addiction Medicine / Psychiatry.

marketed Opioid receptor antagonist Mu, delta, and kappa opioid receptors Addiction Medicine / Psychiatry Small molecule

Target snapshot

Naltrexone Tablet and Placebo Patch (Naltrexone Tablet and Placebo Patch) — The Scripps Research Institute. Naltrexone blocks opioid receptors to reduce cravings and reward-seeking behavior, while the placebo patch serves as a control in this combination formulation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naltrexone Tablet and Placebo Patch TARGET	Naltrexone Tablet and Placebo Patch	The Scripps Research Institute	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)
Nalmefene HCl injection	Nalmefene HCl injection	Leiden University Medical Center	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
long-lasting injectable naltrexone	long-lasting injectable naltrexone	State University of New York - Upstate Medical University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
XR-NTX 380 mg, intramuscular injection	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class